Advances in Cancer Immunotherapy™ – Washington, D.C.

Thursday, Oct. 8, 2020

Organizers:
Kellie Gardner, NP – Georgetown Lombardi Comprehensive Cancer Center
Geoffrey T. Gibney, MD – Georgetown Lombardi Comprehensive Cancer Center
Stephen Liu, MD – Georgetown Lombardi Comprehensive Cancer Center

ACI-Washington, D.C., Live Virtual Program

This program has already taken place.

Program Agenda

Oct. 8, 2020 Program

2:45–3:00 p.m.	Welcome, Introduction, SITC Resources
Session I: Introduction to Cancer Immunotherapy
3:00–3:30 p.m.	Basic Principles of Cancer Immunotherapy Ben Levy, MD – Johns Hopkins University
Session II: Immunotherapy in Practice
3:30–4:00 p.m.	Immunotherapy for the Treatment of Skin Cancers Geoffrey T. Gibney, MD – Georgetown Lombardi Comprehensive Cancer Center
4:00–4:30 p.m.	Immunotherapy for the Treatment of Lung Cancer Chul Kim, MD – Georgetown Lombardi Comprehensive Cancer Center
4:30–5:00 p.m.	Immunotherapy for the Treatment of Head and Neck Cancers Ranee Mehra, MD – University of Maryland
5:00–5:15 p.m.	Break
5:15–5:45 p.m.	Immunotherapy for the Treatment of Hematologic Malignancies Kieron Dunleavy, MD – George Washington University
5:45–6:15 p.m.	Immunotherapy for the Treatment of Genitourinary Malignancies Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
6:15–6:45 p.m.	Immunotherapy for the Treatment of Additional Solid Tumors: Breast Cancer Neelima Denduluri, MD – Virginia Cancer Specialists
6:45–7:00 p.m.	Break
Session III: Immunotherapy Challenges and Beyond
7:00–7:30 p.m.	Toxicity Management Kellie Gardner, NP – Georgetown Lombardi Comprehensive Cancer Center
7:30–8:00 p.m.	Practical Barriers in Cancer Immunotherapy Alexander I. Spira, MD, PhD, FACP – Virginia Cancer Specialists
8:00–8:30 p.m.	What's Next for Cancer Immunotherapy? Mario Sznol, MD – Yale University
8:30–8:35 p.m.	Closing Remarks

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

Describe the rationale for common approaches to cancer immunotherapy.
Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
Implement cancer immunotherapy treatments for skin cancers, lung, genitourinary, head and neck, hematologic cancers, and/or additional solid tumors into clinical practice appropriately.
Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Postgraduate Institute for Medicine SITC Logo

The 2019-2020 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Registration Rates

2019-2020 Continuing Education Information

Download PDF Flyer

Pre-Program Course

Introduction to Immunology – Third Edition

Participation in this free, CME-, CPE-, CNE- and MOC-certified online pre-program course is strongly recommended as it contains information that will not be covered at the program.

This updated, interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program.

Click here to access the course.

Advances in Cancer Immunotherapy™ – Washington, D.C.

Oct. 8, 2020 Program

The 2019-2020 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Pre-Program Course

Introduction to Immunology – Third Edition

Learn More

Membership Links

Get Involved